Building a biotech in a downturn: 3 lessons from VCs and startup CEOs
BioPharma Dive – Read three takeaways from a panel hosted by BioPharma Dive featuring Scribe Therapeutics CEO Benjamin Oakes.
Read MoreThe latest
BioPharma Dive – Read three takeaways from a panel hosted by BioPharma Dive featuring Scribe Therapeutics CEO Benjamin Oakes.
Read More
In Vivo – In September, Sanofi received non-exclusive rights to use Scribe Therapeutics, Inc.’s proprietary CRISPR genome editing technologies and platform of wholly owned enzymes to create ex vivo natural killer cell therapies for cancer.
Read More
Bio-IT World – The agreement grants Sanofi non-exclusive rights to Scribe’s proprietary CRISPR platform of wholly owned enzymes to create ex vivo NK cell therapies.
Read More
Pharmaceutical Technology – Scribe’s CasX-Editors (XE), a suite of custom engineering genome editing and delivery tools based on new foundations such as the CasX enzyme, will back Sanofi’s developing NK cell therapies pipeline for cancer.
Read More
Scrip – Sanofi is turning to gene-editing pioneer Jennifer Doudna and her CRISPR-CasX-based Scribe Therapeutics, Inc. to help it take its next steps in developing potential off-the-shelf cancer therapeutics derived from engineered natural killer (NK) cells.
Read More
BioWorld – Venture-backed startup Scribe Therapeutics Inc. landed a $25 million up-front payment and a chance at more than $1 billion in milestones by granting Sanofi SA license to genome-editing technology for multiple oncology targets.
Read More
BioCentury – Scribe Therapeutics Inc. said Tuesday it will grant Sanofi non-exclusive rights to its CasX-Editor technology for multiple undisclosed oncology targets in engineered NK cell therapies.
Read More
The Pharma Letter – Californian genetic medicine company Scribe Therapeutics has scored a major strategic collaboration with French giant Sanofi.
Read More
Genetic Engineering and Biotechnology News – Sanofi and Scribe Therapeutics will partner to develop CRISPR-based cell therapies to fight cancer, the companies said today, through a collaboration that could generate more than $1 billion for the CRISPR drug developer whose co-founders include Nobel laureate Jennifer Doudna, PhD, of UC Berkeley.
Read More
BioPharma Dive – Sanofi will partner with the Californian biotechnology company Scribe Therapeutics in a deal that extends its exploration of new ways to build cancer cell therapies.
Read More
MedCity News – Sanofi is collaborating with Scribe Therapeutics to use the startup’s CRISPR technology to create cell therapies based on natural killers, a type of immune cell that has cancer-killing capabilities.
Read More
FirstWord Pharma – Sanofi entered into an agreement to use Scribe Therapeutics’ CRISPR genome editing technologies to enable genetic modification of novel natural killer (NK) cell therapies for cancer.
Read More
BioSpace – Under the terms of the deal, Sanofi picks up non-exclusive rights to Scribe’s CRISPR platform of wholly owned enzymes.
Read More
Fierce Biotech – Sanofi has teamed up with Scribe Therapeutics to write the next chapter in its natural killer (NK) cell therapy story, paying $25 million upfront and committing to $1 billion in biobucks for access to a CRISPR platform.
Read More
Endpoints News – The Paris-based giant’s head of oncology research and its chief of genomic medicine have settled on Scribe Therapeutics’ CasX editing tech for their work on NK cells.
Read More
Endpoints News – “CRISPR-by-design” is the idea behind Scribe Therapeutics, a company spun out from Jennifer Doudna’s Nobel-winning lab that’s competing in a closely-tracked field of genome editor companies just starting to make their way to the clinic.
Read More
The Real Deal – Scribe Therapeutics, a molecular engineering company, is the latest notable lessee after securing a building at the Research Park at Marina Village in Alameda.
Read More
TIME – [Ben Oakes’] team has pioneered a CRISPR system relying on a different enzyme, or DNA-cutting molecule, than the original CRISPR platform, and in animal models of ALS, the system seems to edit the targeted mutations more efficiently and contribute to a longer lifespan for the animals than the original CRISPR platform.
Read More
MIT Technology Review – As CEO of Scribe Therapeutics, Benjamin Oakes, 33, is working to optimize novel CRISPR enzymes and ways to package the gene-editing systems to solve those problems.
Read More
Genetic Engineering and Biotechnology News – CEO Benjamin Oakes recently discussed the Biogen collaboration, and his company’s progress in developing its genome editing technology, in an exclusive interview with GEN Edge.
Read More
Inside Precision Medicine – Biogen has exercised an option for an additional disease target in gene therapy with Scribe Therapeutics. This is part of the companies’ ongoing research collaboration to develop and commercialize CRISPR-based therapeutics.
Read More
Pharma Manufacturing – Scribe, headquartered outside of San Francisco, focuses on creating gene therapies using CRISPR technology and custom engineered enzymes. The company’s custom platforms help it to overcome the technological hurdles that other companies in the field face, said Oakes.
Read More
Fierce Biotech – Biogen is double-dipping into a 2020 collaboration with Scribe Therapeutics, exercising its option for an additional neurological disease target in gene therapy using the biotech’s CRISPR technology.
Read More
Seeking Alpha – Biogen (NASDAQ:BIIB) has exercised an option to develop another gene therapy disease target as part of a collaboration with Scribe Therapeutics.
Read More
San Francisco Business Times – Scribe Therapeutics CEO Benjamin Oakes is honored in the San Francisco Business Times’ 40 Under 40 Class of 2022.
Read More
BIOS Podcast – An interview with Scribe co-founders Ben Oakes and Dave Savage on the future of genetic medicine.
Read More
Science in Society Podcast – A chat with Dr. Benjamin L. Oakes on what CRISPR is, how it revolutionized biological research, and how Scribe Therapeutics will take it to its next generation.
Read More
CFO – Biotech firm Scribe Therapeutics appointed David Parrot as chief financial officer. Parrot joins the company from Barclays, where he was a managing director responsible for building its West coast life sciences and biotechnology investment banking business.
Read More
CFO Dive – Former Barclays executive David Parrot is bringing a number of lessons learned from his more than two-decade career in life sciences investment banking to his new role as CFO of biotech firm Scribe Therapeutics.
Read More
Fierce Biotech – David Parrot is the new CFO of Scribe Therapeutics, a molecular engineering company focused on CRISPR-based meds, after serving as a managing director at investment bank Barclays.
Read More
Endpoints News – One of Jennifer Doudna’s CRISPR startups, Alameda, CA-based Scribe Therapeutics, has corralled David Parrot as CFO and George Manning as controller.
Read More
BioSpace – Life sciences companies continue to bolster their leadership teams as they prepare for the next phase of growth.
Read More
The Wall Street Journal – Scribe Therapeutics Inc., an Alameda, Calif.-based biotech startup also co-founded by Dr. Doudna, is developing custom-engineered enzymes for Crispr-based treatments for neurodegenerative and other diseases. Scribe’s technologies are distinct from earlier approaches, co-founder and CEO Benjamin Oakes said.
Read More
BioCentury – Scribe Therapeutics Inc. hired David Parrot as CFO. Parrot was managing director, head of west coast life science investment banking at Barclays Investment Bank. Scribe is developing custom enzymes and delivery modalities for CRISPR and was co-founded by Jennifer Doudna.
Read More
BioWorld – Scribe Therapeutics Inc., of Alameda, Calif., appointed David Parrot chief financial officer and George Manning controller.
Read More
Business Insider – With a busy 2022 ahead for the gene-editing industry, Insider identified the top 18 companies to know that are leading the space.
Read More
Genetic Engineering and Biotechnology News – Scribe scientists hone CasX enzymes so that they acquire characteristics such as enhanced specificity. Oakes describes this as an “engineering first” philosophy, where the desired properties of the system are chosen in advance and intentionally designed, rather than being left to chance or nature.
Read More
Business Insider – Scribe’s main enzyme, CasX, is also smaller and more efficient at making edits, Oakes said. This group of companies often searches nature for new enzymes and then tinkers with them in a lab, aiming to make a better editing tool at the end.
Read More
California Life Sciences – Scribe Therapeutics named Rising Star in the 2021 Pantheon Awards recognizing companies and individuals making significant scientific, business, and community contributions across California.
Read More
Biocom California – Scribe Therapeutics CEO Benjamin Oakes selected as a winner of the 6th annual Catalyst Awards.
Read More
Business Insider – Scribe CEO Benjamin Oakes is carving out a space in the gene-editing field by developing what he calls a “genetic scalpel.”
Read More
Business Insider – Cofounded by CRISPR discoverer Jennifer Doudna and two former researchers in her University of California lab, Scribe is pursuing its own twist on CRISPR. While the standard gene-editing approach uses an enzyme called Cas9, Scribe is developing a smaller version called CasX, which could allow for more applications of CRISPR.
Read More
MedTech Breakthrough Awards – Scribe Therapeutics wins Best New Technology Solution – Drug Development.
Read More
Fast Company – Medical innovations that save lives, extend longevity, or increase access to care.
Read More
Bio-IT World – $100M: Series B for Custom Gene Editing. The capital will be used to further develop Scribe’s suite of custom gene editing and delivery technologies, as well as to advance a pipeline of therapeutics for neurodegeneration and additional diseases with high unmet need.
Read More
Nanalyze – The company has raised a whopping $120 million from the likes of Andreessen Horowitz to build out a suite of CRISPR technologies designed to treat genetic diseases.
Read More
a16z Bio Clubhouse – a16z general partners Vineeta Agarwala and Vijay Pande talk to guest Ben Oakes, cofounder, President and CEO of Scribe Therapeutics in a conversation on the power of engineering gene editors, the transition from academia to a startup, and how to select the first indication to target with a novel bio platform.
Read More
Endpoints News – The annual 20 Under 40 list features CEO Benjamin Oakes and how his dive inside the human mind colors his leadership role at gene editing startup Scribe Therapeutics.
Read More
PMLiVE – Scribe’s technology platform can create custom CRISPR molecules that are specifically designed for therapeutic use within the body, overcoming the limitation of using existing enzymes that may lead to ‘poor editing outcomes’.
Read More
Endpoints News – The California-based biotech will use that cash to continue developing their engineering platform, while bringing forward a pipeline that includes a Biogen-partnered ALS treatment.
Read More
Chemical & Engineering News – The start-up is applying protein engineering to create new CasX enzymes for neurodegenerative diseases and more.
Read More
FierceBiotech – Rather than “shoehorning” enzymes that evolved to work well in bacteria—but not in humans—into treatments for human disease, Scribe is engineering CRISPR molecules from scratch.
Read More
Forbes – Instead of relying on wild-type or naturally occurring Crispr molecules such as Cas9, Scribe Therapeutics have built their own, highly-specialized varieties.
Read More
Crunchbase News – Molecular engineering company Scribe Therapeutics has completed an oversubscribed $100 million round of Series B financing to further develop its “CRISPR by design” platform, as well as advance its pipeline of genetic treatments.
Read More
Genetic Engineering & Biotechnology News – Scribe—one of a new wave of gene editing biotech companies—focuses on developing CRISPR-based treatments through its genetic modification platform, designed to build and apply its suite of CRISPR technologies designed for therapeutic use.
Read More
BioWorld – Scribe Therapeutics Inc. raised $100 million in a series B round to continue its engineering-intensive approach to developing CRISPR-based therapies that employ custom-designed CasX enzymes.
Read More
Technology Networks – Scribe Therapeutics co-founder and CEO Benjamin Oakes sat down for an interview on the company’s next steps in “fulfilling the promise of CRISPR” and how it will navigate some of the challenges associated with developing CRISPR-based therapeutics, including efficacy, scale-up and high costs.
Read More
San Francisco Business Times – The Alameda-based biotech startup will use the fresh capital to expand its team and advance the company’s specialized approach to gene editing in the hopes of creating new treatments for a host of unmet diseases.
Read More
Barron’s – Gene editing is advancing so quickly that next-generation technologies are already on the heels of Crispr-Cas9.
Read More
BioSpace – The NextGen Bio Class of 2021 is a stellar group of companies that are already making an enormous impact on the industry now and will continue into the future.
Read More
Medium – Future Human – Scribe Therapeutics of Alameda, California, is using yet another form of CRISPR dubbed X-editing. Co-founded by CRISPR pioneer and Nobel winner Jennifer Doudna, PhD, the company will use the new gene-editing tool to develop treatments for neurological diseases.
Read More
The Scientistt Podcast – Benjamin L. Oakes is the Founder and CEO of Scribe Therapeutics, a company rewriting the story of disease and engineering the future of genetic medicine.
Read More
Nature Biotechnology – Startup Scribe Therapeutics, spun out of Jennifer Doudna’s lab, emerged from stealth on 6 October with a next-generation CRISPR technology, armed with a $20-million series A round and a collaboration with Biogen.
Read More
Biocom – Another of Doudna’s spin-outs, Scribe Therapeutics, just recently announced their plans to build a platform for CRISPR-based genetic medicine to create therapies for diseases like genetically driven ALS. The company’s tools and mission have the potential to dramatically accelerate CRISPR’s applications into the clinical setting.
Read More
CRISPR Medicine News – California-based gene-editing company Scribe Therapeutics recently unveiled its plans to develop the most advanced platform for breakthrough CRISPR-based genetic medicines.
Read More
Genetic Engineering & Biotechnology News – Best known for her pioneering work in the discovery of CRISPR, Jennifer Doudna, PhD, professor at the University of California, Berkeley, doesn’t stop or, it seems, even slow down. As of yesterday morning, Doudna can add “accept Nobel Prize” to her to-do list as she, along with Emmanuelle Charpentier, PhD, was awarded the 2020 Nobel Prize in Chemistry.
Read More
ALS News Today – Founded by the scientists who originally invented CRISPR, Scribe has developed novel, custom-CRISPR tools, using a technology called X-Editing. This advanced gene-editing platform has greater editing activity and higher specificity, meaning that it can edit the target gene with greater precision than other CRISPR tools currently available.
Read More
pharmaphorum – Scribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 million deal with Biogen.
Read More
Clinical OMICs – This week, another Doudna lab spin out, Scribe Therapeutics, came out of stealth mode to announce their plans to build a platform for CRISPR-based genetic medicine with news of a new Biogen collaboration to create therapeutics for genetically-driven ALS.
Read More
Pharmaceutical Business Review – Molecular engineering company Scribe Therapeutics has entered into a research collaboration with Biogen for the development of CRISPR-based genetic medicines for neurological diseases.
Read More
FierceBiotech – CRISPR evolved in bacteria as a form of “genetic vandalism,” as George Church, Ph.D., puts it, to fend off pathogens. That means it works very well in bacteria but runs into various obstacles when researchers try to put it to work in humans. Jennifer Doudna’s latest CRISPR company plans to surmount those hurdles with an entirely new CRISPR platform that does not rely on molecules found in nature.
Read More
BioWorld – Scribe Therapeutics Inc., another CRISPR-based genome editing firm out of the Jennifer Doudna stable, launched with $20 million in series A funding and a deal with Biogen Inc. in amyotrophic lateral sclerosis (ALS), which brings in another $15 million up front and up to $400 million in development and commercial milestones.
Read More
BioCentury – Scribe is carving out a new space in the gene editing landscape with a next-generation version of the technology from Jennifer Doudna’s lab that substitutes engineered CRISPR enzymes for their natural counterparts.
San Francisco Business Times – Hoping to take the CRISPR genome-editing tool to the next level of drug development, startup Scribe Therapeutics Inc. said Tuesday that it landed a potential $400 million neurodegenerative disease deal with Biogen Inc.
Read More
Xconomy – The first generation of CRISPR-based therapies showed how the technology can edit DNA, making genetic fixes to unwanted mutations. But those treatments use the CRISPR system as scientists found it in nature, which means it still has limitations when applied to humans, says Benjamin Oakes, CEO of Scribe Therapeutics.
Read More
Chemical & Engineering News – Scribe Therapeutics, a biotech firm focused on developing next-generation gene-editing technology, has raised $20 million in its first major round of financing, backed by Andreessen Horowitz. The firm separately unveiled a deal with Biogen to develop CRISPR-based treatments for amyotrophic lateral sclerosis (ALS).
Read More
Endpoints News – Three years ago, Jennifer Doudna gathered with two postdocs and a fellow biochemist around a circular table on the second floor of UC Berkeley’s energy biosciences building, where they tried to answer a question: What, precisely, would the best gene editor look like?
Read More
San Francisco Business Times – Jennifer Doudna’s string of companies, including an Alameda startup, have covered everything from agriculture to a Covid diagnostic to potential drugs.
Read More
Reuters – U.S. drugmaker Biogen Inc and gene-editing startup Scribe Therapeutics Inc will jointly develop therapies for treating underlying genetic causes of amyotrophic lateral sclerosis (ALS), a fatal neurological disorder better known as Lou Gehrig’s disease.
Read More
TechCrunch – A new company called Scribe Therapeutics founded by two former members of CRISPR pioneer Jennifer Doudna’s UC Berkely genetics lab (alongside Doudna herself) launched on Tuesday, debuting a platform designed specifically to help develop and engineer new therapeutics based on CRISPR for addressing specific diseases, with permanent treatments in patients.
Read More
Forbes – What if you had a tool to change the genetic instructions that cause disease? That’s what San Francisco-based Scribe Therapeutics hopes to do with its next-generation platform for gene editing.
Read More
Chemical & Engineering News – Jennifer Doudna’s lab at the University of California, Berkeley, published a detailed study on a genetically and structurally distinct CRISPR enzyme called CasX, which makes staggered breaks during its cutting of the DNA double helix.
Read More
Chemical & Engineering News – CasX, first described in 2016, is smaller than its more famous cousins, Cas9 and Cas12a. This makes it a potentially better candidate for medicinal use as the field turns to viruses to try to get CRISPR systems into the human body.
Read More
Drug Discovery & Development – While CRISPR Cas9 remains a mainstay in the genomics world, researchers have now found a much smaller protein called CasX that could be used for gene editing.
Read More
New Atlas – In new tests, the researchers have found that it is effective at editing the human genome, as well as that of E. coli.
Read More
Interesting Engineering – New research is now revealing CasX is a viable alternative to Cas9. The gene editor was sourced from a microbe database found in groundwater and sediment, and it works in both bacteria and human cells.
Read More
Silicon Republic – CRISPR-Cas9 has revolutionised gene editing, but a new variant of the technology may be far superior.
Read More
Futurism – Researchers from UC Berkeley have discovered that CasX is capable of editing human cells, and it doesn’t carry with it some of the issues involved in Cas9 editing — potentially putting us one step closer to safely gene-editing humans.
Read More
Scribe Therapeutics Inc., a molecular engineering company pioneering a CRISPR by Design™ platform for genetic medicine, today announced it will participate in four upcoming conferences.
Read More
Scribe Therapeutics Inc., a molecular engineering company pioneering a CRISPR by Design™ platform for genetic medicine, today announced it will participate in two upcoming investor conferences.
Read More
Scribe Therapeutics Inc. today announced a strategic collaboration with Sanofi for the use of Scribe’s CRISPR genome editing technologies to enable genetic modification of novel natural killer (NK) cell therapies for cancer.
Driven by ongoing growth, CRISPR and molecular engineering company expands East Bay headquarters and bolsters management team with trio of new vice presidents
Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, today announced its participation in the virtual Biopharma Private Company Connect event hosted by SVB Securities on July 20-21, 2022.
Read More
CRISPR molecular engineering company co-founded by Nobel Laureate Jennifer Doudna continues to accelerate the development of best-in-class in vivo CRISPR-based medicines through the expansion of its ongoing collaboration with Biogen
CRISPR and molecular engineering company scheduled to join panel discussing gene editing innovations
Former Barclays head of west coast biotech franchise and previous Allogene assistant controller join CRISPR and molecular engineering company co-founded by Nobel Laureate Jennifer Doudna developing proprietary technologies for breakthrough genetic medicines
Scribe’s fully integrated evergreen platform accelerates the development of best-in-class in vivo therapies that treat the underlying cause of disease
Honored for the development of a method for genome editing, Scribe co-founder and scientific advisor Jennifer Doudna continues to advance breakthroughs in CRISPR and genetic medicine
Read More
Scribe Therapeutics unveils fully integrated platform for engineering breakthrough CRISPR-based genetic medicines, announces Series A led by Andreessen Horowitz and collaboration with Biogen Inc. focused on development of novel genetic medicines for neurodegeneration
Read More
Scribe Therapeutics to collaborate with Biogen to develop CRISPR-based genetic medicines for neurological diseases, including ALS
Read More